BioScrip Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
BioScrip (BIOS) PT Raised to $4 at Jefferies; Reiterates Buy
August 9, 2017 8:35 AM EDTJefferies raised its price target on BioScrip (NASDAQ: BIOS) to $4.00 (from $3.00) while maintaining a Buy rating following 2Q. EBITDA of $10MM was ahead of consensus and nearly doubled on a sequential basis, while Core revenue was up 2% Q/Q and grew to 73.1% of total... More
BioScrip (BIOS) Misses Q2 EPS by 14c, Revs Modestly Lower; Reiterates Outlook
August 8, 2017 8:03 AM EDTBioScrip (NASDAQ: BIOS) reported Q2 EPS of ($0.26), $0.14 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $218.1 million versus the consensus estimate of $220.17 million.
2017 Guidance
The Company is reiterating its prior guidance of adjusted EBITDA in the range of... More
